Volume 19, Number 11—November 2013
Dispatch
Severe Fever with Thrombocytopenia Syndrome, South Korea, 2012
Kye-Hyung Kim1, Jongyoun Yi1, Gayeon Kim, Su Jin Choi, Kang Il Jun, Nak-Hyun Kim, Pyoeng Gyun Choe, Nam-Joong Kim, Jong-Koo Lee, and Myoung-don Oh
Table
Laboratory findings of the patient with severe fever with thrombocytopenia syndrome, South Korea, 2012*
| Laboratory test (reference range) | Day 2 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | Day 9 | Day 10 |
|---|---|---|---|---|---|---|---|---|
| Hematocrit, % (36–48) | NA | NA | 30 | 30 | 38 | 32 | 34 | 20 |
| Hemoglobin, g/dL (12–16) | 12.9 | 13.6 | 12.4 | 12.4 | 12.9 | 12.8 | 9.9 | 7.0 |
| Leukocytes, cells/μL (4,500–10,000) | 1,800 | 1,300 | 1,600 | 1,600 | 2,100 | 3,150 | 4,300 | 4,700 |
| Neutrophils, % (50–75) | 47 | 60 | 56 | 51 | 76 | 35 | 32 | 33 |
| Lymphocytes, % (20–44) | 36 | 36 | 39 | 41 | 18 | 58 | 57 | 62 |
| Atypical lymphocytes, % (0) | NA | NA | NA | NA | 4 | 5 | 8 | 3 |
| Platelets, /μL (130,000–400,000) | 136,000 | 98,000 | 50,000 | 25,000 | 32,000 | 70,000 | 159,000 | 116,000 |
| AST, IU/L (0–40) | 56 | NA | 180 | 383 | 537 | 1059 | 2279 | NA |
| ALT, IU/L (0–40) | 32 | NA | 66 | 115 | 137 | 199 | 403 | NA |
| Creatine kinase, IU/L (20–270) | NA | NA | NA | 5,127 | 6,966 | 7,830 | 15,224 | NA |
| LDH, IU/L (100–225) | NA | NA | NA | NA | NA | 5270 | NA | NA |
| Creatinine, mg/dL (0.7–1.4) | NA | 0.60 | 0.70 | NA | 0.59 | 0.99 | 2.17 | 3.01 |
| aPTT, sec (26–35.3) | NA | NA | NA | 44.1 | 45.4 | 75.6 | 71.6 | >400 |
| Prothrombin time, INR (0.8–1.2) | NA | NA | NA | 0.98 | 0.99 | 1.08 | 1.06 | >25 |
| Fibrinogen, mg/dL (230–380) | NA | NA | NA | 172 | 151 | 136 | 124 | 57 |
*Day 1 was the onset day of the illness. Platelets were transfused on day 7 and day 9, and fresh frozen plasma was transfused on day 9 and day 10. Creatinine kinase-MB levels were 7, 5, 25.7, 117.5 and 186.2 ng/mL on days 6, 7, 8, 9, and 10, respectively (reference range 0.6–6.3 ng/mL). No anticoagulants were used during the hospitalization and for the renal replacement therapy. NA, not available; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; aPTT, activated partial prothromboplastin time; INR, international normalized ratio.
1These authors contributed equally to this article.
Page created: August 07, 2013
Page updated: August 07, 2013
Page reviewed: August 07, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.